Ms. Shashlo joined Tobira from Incyte Corporation where she held a similar role as the VP of Regulatory Affairs and Quality Assurance. Prior to Incyte, Angie spent several years working with start-up companies such as Genaera, Vitagen and Ligand in a variety of roles including Project Management. Angeline spent many years working for larger pharmaceutical companies such as Wyeth and Upjohn during the first half of her 25-year career in positions of increasing responsibility. Angie received her Bachelor of Science in Pharmacy from the University of Michigan.
Dr. Rheingold brings over 29 years of experience in new product scale-up, formulation development and manufacturing to Tobira Therapeutics. Jay has successfully brought over 25 products to market during his tenure at Lederle, Hoffman-LaRoche, Bristol-Myers Squibb and Organon pharmaceutical companies. He received his doctorate in Pharmaceutical Sciences from the University of Connecticut. Jay joins Tobira from Barrier Therapeutics, where he held the position of Vice-President.
About Tobira Therapeutics, Inc.
Tobira Therapeutics is a private biopharmaceutical company which is
focused on developing and commercializing innovative antiviral compounds to
treat HIV disease. The company was founded in 2006 by Eckard Weber, MD, a
partner at the venture capital firm Domain Associates, to develop novel
treatments for HIV disease. Tobira has assembled a highly experienced
management team with decades of clinical and commercial development
experience specifically in HIV/AIDS drug development.
|SOURCE Tobira Therapeutics Inc.|
Copyright©2008 PR Newswire.
All rights reserved